In our recent Metastatic May campaign, the theme was ‘The Cost of Living’. Living with metastatic breast cancer affects personal finances, careers, and overall income. But we also explored the
What price survival? I think I’m officially a long-term metastatic breast cancer survivor. I mean I have just passed five years since diagnosis and when I looked up the average
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)
